异丙托溴铵联合头孢他啶治疗慢性阻塞性肺炎的疗效

doi:10.3969/j.issn.1001-8131.2022.05.007

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (440 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the therapeutic effect of ipratropium bromide combined with ceftazidime on chronic obstructive pneumonia. Methods A total of 92 patients with chronic obstructive pneumonia were selected as the study subjects.They were divided into control group and observation group by random number table method,with 46 cases in each group.Both groups received conventional treatment.On this basis,the control group was treated with ceftazidime for injection,and the observation group was treated with ipratropium bromide inhalation aerosol combined with ceftazidime for injection.Both groups were treated for 2 weeks.The levels of inflammatory indicators（IL-6,TNF-α,CRP）and pulmonary function indicators（FEV1/FVC,MMEF,PEF）before treatment and 2 weeks after treatment were compared between the two groups,and the incidence of adverse reactions during treatment was recorded. Results After 2 weeks of treatment,the levels of serum IL-6,TNF-α and CRP in the two groups were lower than those before treatment,and the observation group was lower than the control group,the difference was statistically significant（P<0.05）.After 2 weeks of treatment,the levels of FEV1/FVC,MMEF and PEF in the two groups were higher than those before treatment,and the observation group was higher than the control group,and the difference was statistically significant（P<0.05）.During the treatment period,there was no statistically significant difference in the incidence of adverse reactions between the two groups（P<0.05）. Conclusion Ipratropium bromide combined with ceftazidime in the treatment of chronic obstructive pneumonia can effectively reduce the degree of inflammation in the body and improve lung function.

Key words： Chronic obstructive pneumonia Ipratropium bromide Ceftazidime Inflammatory response Lung function

Received: 06 August 2021

PACS:

R563.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Ruimei
	Li Mingming
	Ma Kaiyue

Cite this article:

Zhang Ruimei,Li Mingming,Ma Kaiyue. Efficacy of Ipratropium Bromide Combined with Ceftazidime in the Treatment of Chronic Obstructive Pneumonia[J]. journal1, 2022, 42(5): 16-18.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.05.007 OR http://www.hrbyybjb.org.cn/EN/Y2022/V42/I5/16

[1] 黄菲菲,张荣贵.祛痰利肺汤加减对慢性阻塞性肺炎急性加重期咳喘疗效及血清炎性因子的影响[J].世界中西医结合杂志,2020,15(3):146-148.
[2] 陈辅萍. 美罗培南联合莫西沙星治疗慢性阻塞性肺疾病合并感染性肺炎的观察[J].山西医药杂志,2020,38(7):850-852.
[3] 张婷,田硕涵,周颖,等.重症坏死性胰腺炎患者使用头孢他啶/阿维巴坦的案例分析[J].中国临床药理学杂志,2020,36(11):171-173.
[4] 王贝贝,郭小亮,赵丽敏.咳喘顺丸联合异丙托溴铵治疗慢性阻塞性肺气肿的临床研究[J].现代药物与临床,2020,35(12):74-78.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[6] 张蓓蓓,钱剑,申琴.饮食指导联合PRECEDE模式护理对慢性阻塞性肺炎患者肺功能及血清蛋白的影响[J].河北医药,2020,42(21):151-154.
[7] 李丽,朱勇,鲁晓擘.头孢他啶与头孢噻肟钠治疗糖尿病合并肺部感染的疗效比较[J].皖南医学院学报,2018,37(5):26-29.
[8] 谢桃红,冯慧,谢沛洋.槐杞黄颗粒联合头孢他啶对肺炎支原体肺炎患儿炎性因子及免疫功能的影响[J].药物评价研究,2019,42(10):138-141.
[9] 代芳芳,于艳华,娄金丽,等.头孢他啶-阿维巴坦及其他非常用抗菌药物对耐碳青霉烯类肺炎克雷伯菌药敏情况分析[J].北京医学,2020,42(10):95-97.
[10] 李云芳,李建.京制咳嗽痰喘丸联合复方异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].现代药物与临床,2019,34(8):2370-2375.
[11] 陈梅鹃,王滔,王利.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗对慢性阻塞性肺疾病急性加重期疗效观察[J].解放军医学院学报,2018,39(10):51-54.
[12] 徐光辉,王学忠,解卫平.呼吸机面罩雾化吸入异丙托溴铵和布地奈德混悬液治疗急性加重期慢性阻塞性肺病的临床疗效分析[J].广西医科大学学报,2019,36(10):1589-1593.